ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心

• 批准号: 10582677
• 负责人: DAVID P. CARBONE
• 金额: $ 62.16万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-14 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10582677
• 关键词: American College of Radiology Imaging Network; Area; Award; BRAF gene; Biological Markers; Center for Translational Science Activities; Chest; Clinical; Clinical Data; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Detection; Development; Disease; EGFR inhibition; Early Diagnosis; Eastern Cooperative Oncology Group; Enrollment; Epidermal Growth Factor Receptor; Excision; Funding; Genomics; Goals; Grant; Immunologic Markers; Immunotherapy; Institution; Leadership; Lung; Lung Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of thorax; Molecular; Molecular Abnormality; Molecular Analysis; Mutation; National Clinical Trials Network; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Patient-Focused Outcomes; Patients; Pilot Projects; Plasma; Plasma Cells; Play; Poly(ADP-ribose) Polymerase Inhibitor; Precision Medicine Initiative; Precision therapeutics; Prevention; Process; Proteomics; ROS1 gene; Recurrence; Research; Research Personnel; Residual Neoplasm; Resistance; Role; STK11 gene; Science; Selection for Treatments; Specimen; Technology; Testing; Time; Translational Research; Work; biomarker development; biomarker discovery; biomarker driven; biomarker evaluation; cell free DNA; checkpoint inhibition; chemotherapy; clinical care; cohort; companion diagnostics; driver mutation; drug development; epigenetic marker; epigenomics; improved; improved outcome; innovation; lung cancer screening; next generation; novel; novel marker; novel strategies; personalized medicine; phase 3 study; programmed cell death ligand 1; programs; prospective; risk prediction; risk stratification; small cell lung carcinoma; targeted agent; targeted treatment; tumor

PROJECT SUMMARY/ABSTRACT The ECOG-ACRIN Thoracic Integrated Translational Research Center (EA-ITSC) comprises a team of accomplished researchers with a proven track record of collaborative work to improve outcomes for patients with lung cancer. The EA-ITSC, funded in 2014 by the NCI (U10) at the same time as the formation of the National Clinical Trials Network (NCTN), has played a major role in developing novel approaches for risk stratification, molecular testing, and treatment of lung cancer. This group has also been responsible for guiding the development of biomarker-driven clinical trials initiated by the ECOG-ACRIN Thoracic Malignancies Committee. Our highly collaborative team approach includes sharing specimens across institutions, conducting pilot projects that are of direct relevance to NCTN trials and guiding the translational research components of all newly developed ECOG-ACRIN thoracic malignancies trials. Our overarching goal is to develop novel biomarkers to enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination treatment approaches to enhance the efficacy of existing therapies in lung cancer within the context of the NCTN. With this application, we propose to continue our research work with direct relevance to the NCTN, with the following specific aims: 1) To develop genomic, epigenomic, and proteomics approaches to enhance biomarker discovery efforts in ongoing and planned ECOG-ACRIN studies; 2) To conduct pilot studies on existing ECOG- ACRIN and institutional lung cancer tumor specimens that will lead to prospective NCTN clinical trials; and 3) To guide the development of translational research components of ECOG-ACRIN Thoracic trials and promote collaborations with lung cancer SPORE and P01 institutions. The EA-ITSC will have a robust pilot projects program from years 2-6 of this award that will invite participation from all the NCTN network groups, institutions with lung cancer SPORE and P01 awards, to bring the best science to NCTN clinical trials.

项目总结/摘要 ECOG-ACRIN胸部综合转化研究中心（EA-ITSC）由以下团队组成： 一个有成就的研究人员与合作工作的良好记录，以改善患者的结果， 肺癌EA-ITSC于2014年由NCI（U10）资助，同时成立了国家 临床试验网络（NCTN）在开发新的风险分层方法方面发挥了重要作用， 分子检测和肺癌的治疗。该小组还负责指导 开发由ECOG-ACRIN胸部肿瘤委员会发起的生物标志物驱动的临床试验。 我们高度协作的团队方法包括跨机构共享标本，开展试点项目， 与NCTN试验直接相关，并指导所有新的 开发了ECOG-ACRIN胸部恶性肿瘤试验。我们的首要目标是开发新的生物标志物， 提高免疫治疗的疗效，克服对靶向药物的耐药性，并确定联合治疗方案， 在NCTN的背景下，加强现有肺癌治疗方法的疗效。 有了这个应用程序，我们建议继续我们的研究工作与直接相关的NCTN，与 以下具体目标：1）发展基因组学，表观基因组学和蛋白质组学方法，以提高生物标志物 正在进行和计划的ECOG-ACRIN研究中的发现工作; 2）对现有的ECOG-ACRIN研究进行试点研究。 将导致前瞻性NCTN临床试验的ACRIN和机构肺癌肿瘤标本;以及3） 指导ECOG-ACRIN胸部试验的转化研究部分的开发，并促进 与肺癌SPORE和P01机构合作。环境管理局-资讯科技及广播事务委员会将有一个健全的试验计划， 该奖项的第2-6年计划将邀请所有NCTN网络团体，机构 与肺癌SPORE和P01奖项，把最好的科学NCTN临床试验。